Reinfection After Eradication of Helicobacter Pylori Infection (NCT02674802) | Clinical Trial Compass
UnknownNot Applicable
Reinfection After Eradication of Helicobacter Pylori Infection
China3,500 participantsStarted 2015-12
Plain-language summary
Helicobacter pylori is closely related with gastritis, peptic ulcer, gastric cancer and gastric MALT lymphoma, and it may participate in a variety of parenteral diseases. Infection rates of Helicobacter pylori is still high, so effectively eradication is necessary. At present, the eradication therapy has achieved very good curative effect. However, relapse after eradication is unoptimistic. This study has made an analysis for reinfection after eradication of Helicobacter pylori Infection include the retrospective and prospective studies, aims to explore the epidemiological data and related risk factors of Hp reinfection in China.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓1、Retrospective study：
✓. Received regular eradication therapy, 4 to 8 weeks after drug withdrawal , detected of helicobacter pylori and the results were negative
✓. Eradication program and original disease is unlimited
✓. Without any eradication therapyof Hp during the treatment and detection again
✓. before the detection has not used antibiotics, bismuth agent and the traditional Chinese medicine with antibacterial effect in 1 monthor and has not used H2RA and PPI in 2 weeks.
✓. Infected with H. pylori that detected by C-UBT
✓. With out alimentary tract hemorrhage,ulceration and complications of eradication
✓. Eradication program and original disease is unlimited
Exclusion criteria
✕. Pregnancy or breast-feeding women
✕
What they're measuring
1
Helicobacter Pylori Infection
Timeframe: six months
2
Helicobacter Pylori Infection
Timeframe: After regular eradication therapy of Hp for 4 weeks, 8 weeks and 6 months
Trial details
NCT IDNCT02674802
SponsorThe First Affiliated Hospital of Nanchang University
. With the major disease which would influence the research such as liver disease, heart disease, kidney disease, malignant tumor and alcohol poisoning
✕. Participated in other drug research in the past three months
✕. The patient can't express himself correctly such as mental illness and severe neurosis and can't cooperation this test